AbbVie obtained emraclidine, a potential novel M4-selective positive allosteric modulator (PAM), originally commercialised by ...

Scientists have pinpointed the binding site for low-dose ketamine on NMDA receptors, explaining its fast-acting effects on ...

Beijing Primegene Therapeutics Co. Ltd. has patented macrocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) allosteric inhibitors reported to be useful for the ...

Nine-month Results Remain On Track for Net ProfitAd Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 11, 2024-Addex ...

Using analysis from an open-label, long-term treatment study of the RNS ® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

The key difference between emraclidine and Cobenfy is that emraclidine is a selective allosteric M4 agonist which means it ...

Nimbus Therapeutics LLC reported the identification of an allosteric, potent, selective, highly efficacious and noncovalent Werner syndrome helicase (WRN) inhibitor, NTX-452, for the potential ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...